Skip to main content
SpringerLink
Log in

Epidemiologie, Patientenlebensqualität und Behandlungskosten der Hidradenitis suppurativa/Acne inversa

Epidemiology, patient quality of life, and treatment costs of hidradenitis suppurativa/acne inversa

  • Leitthema
  • Published:
Der Hautarzt Aims and scope Submit manuscript

Zusammenfassung

Hidradenitis suppurativa (HS)/Acne inversa (AI) geht mit zahlreichen und relevanten Einschränkungen der Lebensqualität für die Betroffenen und ihre Angehörigen einher. Literaturangaben zur Prävalenz der HS variieren erheblich, sie ist jedoch wahrscheinlich höher als in früheren Publikationen angenommen. Die Versorgung der HS geht mit hohen Kosten für das Gesundheitssystem und die Betroffenen einher. Die Einführung der Biologikatherapie hat zu weiteren Kosten, jedoch auch erheblichem Mehrnutzen in der Versorgung geführt. Angesichts der Komplexität von Diagnostik und Therapie besteht ein besonderer Bedarf an optimierten Versorgungskonzepten, um die Last für die Betroffenen, ihre Angehörigen und das Gesundheitssystem zu reduzieren.

Abstract

Hidradenitis suppurativa/acne inversa (HS) is associated with numerous and relevant restrictions on the quality of life for those affected and their relatives. The exact prevalence of HS varies significantly across studies, but it is likely to be higher than suggested in previous publications. HS care is associated with high costs for the healthcare system and for those affected. The introduction of biologic therapy has led to additional costs, but also to considerable additional benefits in terms of care. In view of the complexity of diagnostics and therapy, there is a particular need for optimized care concepts in order to reduce the burden on those affected, their relatives and the healthcare system.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Abb. 1

Literatur

  1. Alavi A, Farzanfar D, Lee RK et al (2018) The contribution of malodour in quality of life of patients with hidradenitis suppurativa. J Cutan Med Surg 22:166–174

    Article  PubMed  Google Scholar 

  2. Argyropoulou M, Kanni T, Kyprianou M et al (2019) Cost-savings of adalimumab in hidradenitis suppurativa: a retrospective analysis of a real-world cohort. Br J Dermatol 180:1161–1168

    Article  CAS  PubMed  Google Scholar 

  3. Balieva F, Kupfer J, Lien L et al (2017) The burden of common skin diseases assessed with the EQ5D: a European multicentre study in 13 countries. Br J Dermatol 176:1170–1178

    Article  CAS  PubMed  Google Scholar 

  4. Chernyshov PV, Zouboulis CC, Tomas-Aragones L et al (2021) Quality of life in hidradenitis suppurativa. An update. Int J Environ Res Public Health 18:6131

    Article  PubMed  PubMed Central  Google Scholar 

  5. Cosmatos I, Matcho A, Weinstein R et al (2013) Analysis of patient claims data to determine the prevalence of hidradenitis suppurativa in the United States. J Am Acad Dermatol 69:819

    Article  PubMed  Google Scholar 

  6. Cuenca-Barrales C, Molina-Leyva A (2020) Risk factors of sexual dysfunction in patients with hidradenitis suppurativa: a cross-sectional study. Dermatology 236:37–45

    Article  PubMed  Google Scholar 

  7. Fernandez JM, Rizvi OH, Marr KD et al (2021) Itch and pain by lesion morphology in hidradenitis suppurativa patients. Int J Dermatol 60:e56–e59

    Article  PubMed  Google Scholar 

  8. Frings VG, Bauer B, Gloditzsch M et al (2019) Assessing the psychological burden of patients with hidradenitis suppurativa. Eur J Dermatol 29:294–301

    PubMed  Google Scholar 

  9. Garcovich S, Muratori S, Moltrasio C et al (2020) Prevalence of neuropathic pain and related characteristics in hidradenitis suppurativa: a cross-sectional study. J Clin Med 9(12):4046

    CAS  PubMed Central  Google Scholar 

  10. Garg A, Kirby JS, Lavian J et al (2017) Sex- and age-adjusted population analysis of prevalence estimates for hidradenitis suppurativa in the United States. JAMA Dermatol 153:760–764

    Article  PubMed  PubMed Central  Google Scholar 

  11. Garg A, Papagermanos V, Midura M et al (2018) Opioid, alcohol, and cannabis misuse among patients with hidradenitis suppurativa: a population-based analysis in the United States. J Am Acad Dermatol 79:495–500.e1

    Article  PubMed  Google Scholar 

  12. Gaspar K, Hunor Gergely L, Jenei B et al (2021) Resource utilization, work productivity and costs in patients with hidradenitis suppurativa: a cost-of-illness study. Expert Rev Pharmacoecon Outcomes Res 9:1–10

    Google Scholar 

  13. Janse IC, Deckers IE, Van Der Maten AD et al (2017) Sexual health and quality of life are impaired in hidradenitis suppurativa: a multicentre cross-sectional study. Br J Dermatol 176:1042–1047

    Article  CAS  PubMed  Google Scholar 

  14. Jfri AND, O’brien E, Gulliver W, Nikolakis G, Zouboulis CC (2021) Prevalence of hidradenitis suppurativa: A systematic review and meta-regression study. JAMA Dermatol :e211677

  15. Kaaz K, Szepietowski JC, Matusiak L (2018) Influence of itch and pain on sleep quality in patients with hidradenitis suppurativa. Acta Derm Venereol 98:757–761

    Article  PubMed  Google Scholar 

  16. Karagiannidis I, Nikolakis G, Zouboulis CC (2016) Endocrinologic aspects of hidradenitis suppurativa. Dermatol Clin 34:45–49

    Article  CAS  PubMed  Google Scholar 

  17. Kirby JS, Miller JJ, Adams DR et al (2014) Health care utilization patterns and costs for patients with hidradenitis suppurativa. JAMA Dermatol 150:937–944

    Article  PubMed  Google Scholar 

  18. Kirsten NOM, Bechara F et al (2019) HS-QoL: Disease specific instrument to assess quality of life in patients with hidradenitis suppurativa. Oral presentation; 8th Conference of the European Hidradenitis Suppurativa Foundation, Wroclaw, 02.2019

    Google Scholar 

  19. Kirsten N, Petersen J, Hagenstrom K et al (2020) Epidemiology of hidradenitis suppurativa in Germany—an observational cohort study based on a multisource approach. J Eur Acad Dermatol Venereol 34:174–179

    Article  CAS  PubMed  Google Scholar 

  20. Kirsten N, Zander N, Augustin M (2021) Prevalence and cutaneous comorbidities of hidradenitis suppurativa in the German working population. Arch Dermatol Res 313:95–99

    Article  PubMed  Google Scholar 

  21. Kurek A, Peters EM, Chanwangpong A et al (2012) Profound disturbances of sexual health in patients with acne inversa. J Am Acad Dermatol 67:422–428, 428 e421

    Article  PubMed  Google Scholar 

  22. Kurzen H, Kurokawa I, Jemec GB et al (2008) What causes hidradenitis suppurativa? Exp Dermatol 17:455–456 (discussion 457–472)

    Article  CAS  PubMed  Google Scholar 

  23. Lam M, Lai C, Almuhanna N et al (2020) Hidradenitis suppurativa and down syndrome: a systematic review and meta-analysis. Pediatr Dermatol 37:1044–1050

    Article  PubMed  Google Scholar 

  24. Lazic T, Li Q, Frank M et al (2012) Extending the phenotypic spectrum of keratitis-ichthyosis-deafness syndrome: report of a patient with GJB2 (G12R) Connexin 26 mutation and unusual clinical findings. Pediatr Dermatol 29:349–357

    Article  PubMed  Google Scholar 

  25. Lee JH, Kwon HS, Jung HM et al (2018) Prevalence and comorbidities associated with hidradenitis suppurativa in Korea: a nationwide population-based study. J Eur Acad Dermatol Venereol 32:1784–1790

    Article  CAS  PubMed  Google Scholar 

  26. Li M, Hunt MJ, Commens CA (1997) Hidradenitis suppurativa, Dowling Degos disease and perianal squamous cell carcinoma. Australas J Dermatol 38:209–211

    Article  CAS  PubMed  Google Scholar 

  27. Marzano AV, Ceccherini I, Gattorno M et al (2014) Association of pyoderma gangrenosum, acne, and suppurative hidradenitis (PASH) shares genetic and cytokine profiles with other autoinflammatory diseases. Medicine 93:e187

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  28. Matusiak L, Bieniek A, Szepietowski JC (2010) Hidradenitis suppurativa markedly decreases quality of life and professional activity. J Am Acad Dermatol 62:706–708, 708 e701

    Article  PubMed  Google Scholar 

  29. Matusiak L, Szczech J, Kaaz K et al (2018) Clinical characteristics of pruritus and pain in patients with hidradenitis suppurativa. Acta Derm Venereol 98:191–194

    Article  PubMed  Google Scholar 

  30. Mclellan C, Sisic M, Oon HH et al (2018) Preliminary validation of the HS-QoL: a quality-of-life measure for hidradenitis suppurativa. J Cutan Med Surg 22:142–146

    Article  PubMed  Google Scholar 

  31. Molina-Leyva A, Cuenca-Barrales C (2020) Pruritus and malodour in patients with hidradenitis suppurativa: impact on quality of life and clinical features associated with symptom severity. Dermatology 236:59–65

    Article  PubMed  Google Scholar 

  32. Nguyen MT, Borchers A, Selmi C et al (2012) The SAPHO syndrome. Semin Arthritis Rheum 42:254–265

    Article  PubMed  Google Scholar 

  33. Nielsen RM, Lindso Andersen P, Sigsgaard V et al (2020) Pain perception in patients with hidradenitis suppurativa. Br J Dermatol 182:166–174

    Article  CAS  PubMed  Google Scholar 

  34. Nikolakis G, Kaleta KP, Vaiopoulos AG et al (2020) Phenotypes and pathophysiology of syndromic hidradenitis suppurativa: Different faces of the same disease? A systematic review. Dermatology 9:1–25

    Google Scholar 

  35. Nikolakis G, Karagiannidis I, Vaiopoulos AG et al (2020) Endokrine Mechanismen bei der Pathophysiologie der Hidradenitis suppurativa. Hautarzt 71:762–771

    Article  CAS  PubMed  Google Scholar 

  36. Nikolakis GKK, Vaiopoulos A, Kaleta K, Talas J, Becker M, Zouboulis CC (2021) Successful application of secukinumab for the treatment of PsAPSASH syndrome, an alternative phenotype of syndromic hidradenitis suppurativa. F1000 Research 10:381

    Article  PubMed  PubMed Central  Google Scholar 

  37. Onderdijk AJ, Van Der Zee HH, Esmann S et al (2013) Depression in patients with hidradenitis suppurativa. J Eur Acad Dermatol Venereol 27:473–478

    Article  CAS  PubMed  Google Scholar 

  38. Phan K, Charlton O, Smith SD (2020) Hidradenitis suppurativa and polycystic ovarian syndrome: systematic review and meta-analysis. Australas J Dermatol 61:e28–e33

    Article  PubMed  Google Scholar 

  39. Richter T, Nestler-Parr S, Babela R et al (2015) Rare disease terminology and definitions—a systematic global review: report of the ISPOR rare disease special interest group. Value Health 18:906–914

    Article  PubMed  Google Scholar 

  40. Sampogna F, Fania L, Mastroeni S et al (2020) Correlation between depression, quality of life and clinical severity in patients with hidradenitis suppurativa. Acta Derm Venereol 100:adv319

    PubMed  Google Scholar 

  41. Saunte DM, Boer J, Stratigos A et al (2015) Diagnostic delay in hidradenitis suppurativa is a global problem. Br J Dermatol 173:1546–1549

    Article  CAS  PubMed  Google Scholar 

  42. Theut Riis P, Pedersen OB, Sigsgaard V et al (2019) Prevalence of patients with self-reported hidradenitis suppurativa in a cohort of Danish blood donors: a cross-sectional study. Br J Dermatol 180:774–781

    Article  CAS  PubMed  Google Scholar 

  43. Thorlacius L, Cohen AD, Gislason GH et al (2018) Increased suicide risk in patients with hidradenitis suppurativa. J Invest Dermatol 138:52–57

    Article  CAS  PubMed  Google Scholar 

  44. Tzellos T, Yang H, Mu F et al (2019) Impact of hidradenitis suppurativa on work loss, indirect costs and income. Br J Dermatol 181:147–154

    Article  CAS  PubMed  Google Scholar 

  45. Vaiopoulos AG, Nikolakis G, Zouboulis CC (2020) Hidradenitis suppurativa in paediatric patients: a retrospective monocentric study in Germany and review of the literature. J Eur Acad Dermatol Venereol 34:2140–2146

    Article  CAS  PubMed  Google Scholar 

  46. Vlassova N, Kuhn D, Okoye GA (2015) Hidradenitis suppurativa disproportionately affects African Americans: a single-center retrospective analysis. Acta Derm Venereol 95:990–991

    Article  CAS  PubMed  Google Scholar 

  47. Wlodarek K, Glowaczewska A, Matusiak L et al (2020) Psychosocial burden of hidradenitis suppurativa patients’ partners. J Eur Acad Dermatol Venereol 34:1822–1827

    Article  CAS  PubMed  Google Scholar 

  48. Zouboulis CC (2021) Pain Index: a new prospective hidradenitis suppurativa patient-reported outcome measure instrument. Br J Dermatol 184(6):1203–1204

    Article  CAS  PubMed  Google Scholar 

  49. Zouboulis CC (2019) The socioeconomic burden of hidradenitis suppurativa/acne inversa. Br J Dermatol 181:7–8

    Article  CAS  PubMed  Google Scholar 

  50. Zouboulis CC (2021) Hidradenitis suppurativa-specific, patient-reported outcome measures. J Eur Acad Dermatol Venereol 35(7):1420–1421

    Article  CAS  PubMed  Google Scholar 

  51. Zouboulis CC, Del Marmol V, Mrowietz U et al (2015) Hidradenitis suppurativa/acne inversa: criteria for diagnosis, severity assessment, classification and disease evaluation. Dermatology 231:184–190

    Article  PubMed  Google Scholar 

Download references

Danksagung

Die Klinik und Poliklinik für Dermatologie, Venerologie und Allergologie, Universitätsklinikum Würzburg, und die Hochschulklinik für Dermatologie, Venerologie und Allergologie, Immunologisches Zentrum, Städtisches Klinikum Dessau, sind Gesundheitszentren des Europäischen Referenz-Netzwerkes für Seltene und Schwere Hautkrankheiten (ERN Skin, ALLOCATE Skin-Gruppe).

Author information

Authors and Affiliations

  1. Institut für Versorgungforschung in der Dermatologie und bei Pflegeberufen, Universitätsklinikum Hamburg-Eppendorf, Gebäude West 38 (W38), Martinistr. 52, 20246, Hamburg, Deutschland

    N. Kirsten &  M. Augustin

  2. Hidradenitis Suppurativa Foundation e. V., Dessau, Deutschland

    N. Kirsten, G. D. Nikolakis,  D. Presser,  C. C. Zouboulis &  M. Augustin

  3. Klinik und Poliklinik für Dermatologie, Venerologie und Allergologie, Universitätsklinikum Würzburg, Würzburg, Deutschland

    V. Frings,  D. Presser &  M. Goebeler

  4. Hochschulklinik für Dermatologie, Venerologie und Allergologie, Immunologisches Zentrum, Städtisches Klinikum Dessau, Medizinische Hochschule Brandenburg Theodor Fontane und Fakultät für Gesundheitswissenschaften Brandenburg, Dessau, Deutschland

    G. D. Nikolakis &  C. C. Zouboulis

Authors
  1. N. Kirsten
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. V. Frings
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. G. D. Nikolakis
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. D. Presser
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. M. Goebeler
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. C. C. Zouboulis
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. M. Augustin
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to N. Kirsten.

Ethics declarations

Interessenkonflikt

V. Frings und G.D. Nikolakis geben an, dass kein Interessenkonflikt besteht. D. Presser und M. Goebeler waren Prüfarzte in klinischen Studien zur AI/HS der Firmen UCB und Novartis. C.C. Zouboulis hat Berater- und Vortragshonorare von Idorsia, Incyte, InflaRx, Janssen, Novartis, Regeneron und UCB erhalten, die nicht mit diesem Manuskript in Verbindung stehen. Seine Abteilung erhielt Honorare von AbbVie, InflaRx, Novartis und UCB für seine Teilnahme an klinischen Studien. N. Kirsten hat Berater- und Vortragshonorare von AbbVie, Eli Lilly, Janssen, Novartis, UCB, Streamedup, Uluru erhalten und war als Prüfärztin an klinischen Studien zur AI/HS der Firmen UCB, AbbVie, Novartis beteiligt. M. Augustin hat Berater- und Vortragshonorare von AbbVie, Almirall, Amgen, Biogen, Boehringer Ingelheim, Celgene, Centocor, Eli Lilly, GSK, Janssen-Cilag, LEO, Medac, Merck, MSD, Novartis, Pfizer, UCB und XenoPort erhalten und war an klinischen Studien der Firmen AbbVie, Novartis, UCB zur AI/HS als Prüfarzt beteiligt.

Für diesen Beitrag wurden von den Autoren keine Studien an Menschen oder Tieren durchgeführt. Für die aufgeführten Studien gelten die jeweils dort angegebenen ethischen Richtlinien.

Additional information

Die Autoren N. Kirsten und V. Frings haben zu gleichen Teilen als Erstautorinnen zum Manuskript beigetragen.

figure qr

QR-Code scannen & Beitrag online lesen

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Kirsten, N., Frings, V., Nikolakis, G.D. et al. Epidemiologie, Patientenlebensqualität und Behandlungskosten der Hidradenitis suppurativa/Acne inversa. Hautarzt 72, 651–657 (2021). https://doi.org/10.1007/s00105-021-04851-z

Download citation

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00105-021-04851-z

Schlüsselwörter

Keywords

Search

Navigation